Newer therapeutic approaches: spondyloarthritis and uveitis

Rheum Dis Clin North Am. 2006 Feb;32(1):75-90, viii. doi: 10.1016/j.rdc.2005.12.003.


Over the last 5 years considerable progress has taken place in the therapeutic approach to spondyloarthritis (SpA). This progress is due in large part to the development of effective biologic therapies and to improved clinical trial design and implementation. This article summarizes treatment advances in SpA with emphasis on the efficacy and safety of biologic agents in the treatment of psoriatic arthritis, ankylosing spondylitis, undifferentiated spondyloarthropathy, and uveitis.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Antirheumatic Agents / therapeutic use
  • Humans
  • Immunologic Factors / therapeutic use
  • Physical Therapy Modalities
  • Spondylarthritis / therapy*
  • Treatment Outcome
  • Uveitis / therapy*


  • Anti-Bacterial Agents
  • Antirheumatic Agents
  • Immunologic Factors